Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity

Authors: Kort, Jeries ^{1, 2, †, ⁎}, Naleid, Nikolas ³, Oley, Frank ¹, Ignatz-Hoover, James ^{1, 2}, Margevicius, Seunghee ⁴, Fu, Pingfu ⁴, Malek, Ehsan ^{1, 2, ‡}, Cooper, Brenda ^{1, 2}

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2025

Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer.

Authors: O'Donnell, Conor D. J.¹ (AUTHOR) odonnell.conor@mayo.edu, Naleid, Nikolas² (AUTHOR), Siripoon, Teerada^1,3 (AUTHOR), Zablonski, Kevin G.² (AUTHOR), Storandt, Michael H.¹ (AUTHOR), Selfridge, Jennifer E.⁴ (AUTHOR), Hallemeier, Christopher L.⁵ (AUTHOR), Conces, Madison L.⁴ (AUTHOR), Jethwa, Krishan R.⁵ (AUTHOR), Bajor, David L.⁴ (AUTHOR), Thiels, Cornelius A.⁶ (AUTHOR), Warner, Susanne G.⁶ (AUTHOR), Starlinger, Patrick P.⁶ (AUTHOR), Atwell, Thomas D.⁷ (AUTHOR), Mitchell, Jessica L.⁸ (AUTHOR), Mahipal, Amit⁴ (AUTHOR), Jin, Zhaohui⁸ (AUTHOR) jin.zhaohui@mayo.edu

Source: Cancers. Jul2024, Vol. 16 Issue 13, p2407. 14p.

Subject Terms: *RISK assessment, *CANCER relapse, *DATA analysis, *ABLATION techniques, *GENETIC markers, *COLORECTAL cancer, *TUMOR markers, *RETROSPECTIVE studies, *RADIOSURGERY, *METASTASIS, *KAPLAN-Meier estimator, *LOG-rank test, *CANCER chemotherapy, *NUCLEIC acids, *RESEARCH, *EXTRACELLULAR space, *PROGRESSION-free survival, *TUMOR antigens, *HEPATECTOMY, *GENETIC testing, *PATIENT aftercare, *DISEASE risk factors

Utilization of circulating tumor DNA (ctDNA) testing in biliary tract cancers.

Authors: Naleid, Nikolas, Pawar, Omkar, Patell, Kanchi, Conces, Madison, Lumish, Melissa Amy, Selfridge, J. Eva, Mohamed, AMR, Bajor, David L., Chakrabarti, Sakti, Mahipal, Amit

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p644-644, 132p

Safety and efficacy of anti-HER2 agents in the treatment of biliary tract cancers: A systematic review.

Authors: Naleid, Nikolas, Pawar, Omkar, Chakrabarti, Sakti, Jin, Zhaohui, Mangla, Ankit, Mahipal, Amit

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p639-639, 132p

First line atezolizumab + bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.

Authors: Kournoutas, Ioannis, Marell, Paulina S, Peersen, Anina, Gupta, Garima, Akce, Mehmet, Yang, Ju Dong, Chen, Pin-Jung, Naleid, Nikolas, Mahipal, Amit, Sahai, Vaibhav, Thompson, Scott, Jin, Zhaohui, Venkatesh, Sudhakar, Borad, Mitesh J., Babiker, Hani M., Bekaii-Saab, Tanios S., McWilliams, Robert R., Halfdanarson, Thorvardur Ragnar, Ou, Fang-Shu, Tran, Nguyen H.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p532-532, 132p

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials.

Authors: Naleid, Nikolas, Mahipal, Amit, Chakrabarti, Sakti

Source: Biomedicines; Jan2025, Vol. 13 Issue 1, p229, 15p

Subject Terms: PROGRAMMED cell death 1 receptors, DRUG side effects, IMMUNE checkpoint inhibitors, TERMINATION of treatment, GASTROINTESTINAL cancer

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.

Authors: Storandt, Michael H, Zemla, Tyler J, Patell, Kanchi, Naleid, Nikolas, Gile, Jennifer J, Tran, Nguyen H, Chakrabarti, Sakti, Jin, Zhaohui, Borad, Mitesh, Mahipal, Amit

Source: Oncologist; Nov2024, Vol. 29 Issue 11, p986-996, 11p

Subject Terms: THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, PREDICTIVE tests, BEVACIZUMAB, TREATMENT effectiveness, MULTIVARIATE analysis, DESCRIPTIVE statistics, FUNCTIONAL status, RETROSPECTIVE studies, LONGITUDINAL method, KAPLAN-Meier estimator, RESEARCH, HEPATITIS B, CANCER patient psychology, HEPATOCELLULAR carcinoma, LIVER function tests, OVERALL survival, PROPORTIONAL hazards models

Geographic Terms: UNITED States

Systemic treatment post curative-intent intervention based on tumor-informed circulating tumor DNA result for oligometastatic colorectal cancer.

Authors: Siripoon, Teerada, O'Donnell, Conor, Naleid, Nikolas, Starlinger, Patrick, Atwell, Thomas D., Thiels, Cornelius A, Warner, Susanne, Mitchell, Jessica L., Jethwa, Krishan, Hallemeier, Christopher Leigh, Mathis, Kellie Leanne, Shawki, Sherief, Mahipal, Amit, Jin, Zhaohui

Source: Journal of Clinical Oncology; 2024 Supplement, Vol. 42, p84-84, 48p

Multiinstitutional cohort study of patient outcomes in Child-Pugh (CP) B liver function treated with atezolizumab plus bevacizumab (A+B) for hepatocellular carcinoma (HCC).

Authors: Mahipal, Amit, Zemla, Tyler J., Patell, Kanchi, Naleid, Nikolas, Gile, Jennifer, Jin, Zhaohui, Tran, Nguyen H., Borad, Mitesh, Chakrabarti, Sakti, Storandt, Michael H.

Source: Journal of Clinical Oncology; 2024 Supplement, Vol. 42, p50-50, 48p

Real-world assessment of capecitabine and oxaliplatin (CAPOX) tolerability in patients with localized colorectal cancer undergoing curative-intent therapy: A comprehensive single institution analysis.

Authors: Mears, Veronica, Naleid, Nikolas, Kakish, Hanna, Selfridge, J. Eva, Conces, Madison, Lumish, Melissa Amy, Bajor, David L, Mahipal, Amit, Chakrabarti, Sakti

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p90-90, 235p

Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.

Authors: Naleid, Nikolas, Mears, Veronica, Kakish, Hanna, Mahipal, Amit, Chakrabarti, Sakti

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p744-744, 42p

Ten-year overall survival of localized lower thoracic and esophagogastric junction carcinoma receiving trimodality therapy: A National Cancer Database analysis.

Authors: Kakish, Hanna, Naleid, Nikolas, Towe, Christopher W., Hoehn, Richard, Mears, Veronica, Selfridge, J. Eva, Lumish, Melissa Amy, Conces, Madison, Bajor, David L, MOHAMED, AMR, Henke, Lauren E., Dorth, Jennifer Anne, Mahipal, Amit, Chakrabarti, Sakti

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p278-278, 185p

Surveillance of resected metastatic colorectal cancer utilizing circulating DNA.

Authors: Naleid, Nikolas, Zablonski, Kevin, Kakish, Hanna, Lumish, Melissa Amy, Bajor, David L, Selfridge, J. Eva, Conces, Madison, MOHAMED, AMR, Chakrabarti, Sakti, Mahipal, Amit

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p214-214, 235p

MM-537 Impact of Melphalan Dose and CD34+ Cell Infusion on Engraftment and Post-Transplant Complications in Multiple Myeloma (MM) Patients

Authors: Kort, Jeries, Oley, Frank, Naleid, Nikolas, Metheny, Leland, Gallogly, Molly, Malek, Ehsan, Cooper, Brenda

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S508-S508

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196309213.0x000001&indx=1&recIds=ETOCvdc_100196309213.0x000001

POSTER: MM-537 Impact of Melphalan Dose and CD34+ Cell Infusion on Engraftment and Post-Transplant Complications in Multiple Myeloma (MM) Patients

Authors: Kort, Jeries, Oley, Frank, Naleid, Nikolas, Metheny, Leland, Gallogly, Molly, Malek, Ehsan, Cooper, Brenda

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S222-S222

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196317744.0x000001&indx=1&recIds=ETOCvdc_100196317744.0x000001

Dose Adjustment of Melphalan Is Safe and Effective for Certain Patients with MM Undergoing ASCT

Authors: Kort, Jeries, Oley, Frank, Naleid, Nikolas, Metheny, Leland, Gallogly, Molly, Malek, Ehsan, Cooper, Brenda

Source: Transplantation and Cellular Therapy. 29(S):S406-S406

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100180672283.0x000001&indx=1&recIds=ETOCvdc_100180672283.0x000001

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment

Authors: Mears, Veronica, Naleid, Nikolas, Pawar, Omkar, Selfridge, Jennifer Eva, Conces, Madison, Lumish, Melissa, Bajor, David, Mahipal, Amit, Chakrabarti, Sakti

Source: JCO Oncology Practice; 20250101, Issue: Preprints

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Authors: Kort, Jeries, Areti, Sathya Sri, Naleid, Nikolas, Cooper, Brenda W, Malek, Ehsan

Source: In Blood 2 November 2023 142 Supplement 1:6706-6706

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.

Authors: Sidda, Adarsh, Naleid, Nikolas Kristopher, Manu, Gurusidda, Graffeo, Vincent, Jamil, Muhammad Omer

Source: Journal of Investigative Medicine High Impact Case Reports; 7/21/2022, Vol. 10, p1-7, 7p